It’s not the end but it doesn’t help either

Novo Nordisk has disclosed that the FDA issued a refusal-to-file letter regarding the company's marketing application seeking to expand approval of Ozempic (semaglutide) to include a 2-mg dose for the treatment of type 2 diabetes.

Per the company’s press release:

“In the letter, FDA has requested additional information including data relating to a proposed new manufacturing site. While additional information needs to be included in the resubmission, Novo Nordisk believes the already completed clinical trial programme will be sufficient for approval of the label expansion application.”

Now we don’t think this will kill . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

© 2005 - 2021 Diabetic Investor, Inc., all rights reserved. Unless expressly permitted under your written license agreement, you are not authorized to forward or to otherwise copy our newsletter, or any portion thereof, by electronic means or otherwise. 17 U.S.C. §504 provides for statutory damages of up to $150,000 per infringement of a copyright and additional damages.